This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.
Approved for removal of the triple negative breast cancer (tnbc) indication from the device intended use statement and labeling.
| Device | VENTANA PD-L1 (SP142) Assay |
| Generic Name | Immunohistochemistry Assay, Antibody, Programmed Death-ligand 1 |
| Applicant | VENTANA MEDICAL SYSTEMS, INC. |
| Date Received | 2021-09-07 |
| Decision Date | 2021-09-28 |
| PMA | P160002 |
| Supplement | S015 |
| Product Code | PLS |
| Advisory Committee | Pathology |
| Supplement Type | Special (immediate Track) |
| Supplement Reason | Labeling Change - Indications/instructions/shelf Life/tradename |
| Expedited Review | No |
| Combination Product | No |
| Applicant Address | VENTANA MEDICAL SYSTEMS, INC. 1910 East Innovation Park Dr. tucson, AZ 85755 |
| Supplement Number | Date | Supplement Type |
|---|---|---|
| P160002 | Original Filing | |
| S019 | 2022-10-14 | 30-day Notice |
| S018 | 2022-07-12 | 30-day Notice |
| S017 | 2022-02-16 | Special (immediate Track) |
| S016 | 2022-01-28 | 135 Review Track For 30-day Notice |
| S015 | 2021-09-07 | Special (immediate Track) |
| S014 | 2021-02-22 | Real-time Process |
| S013 | 2020-08-26 | Real-time Process |
| S012 | 2020-01-21 | Normal 180 Day Track |
| S011 | 2020-01-13 | Real-time Process |
| S010 | 2019-08-22 | Real-time Process |
| S009 | 2018-09-14 | Panel Track |
| S008 | ||
| S007 | 2018-06-18 | Real-time Process |
| S006 | 2018-06-14 | Normal 180 Day Track |
| S005 | ||
| S004 | ||
| S003 | 2017-07-17 | 30-day Notice |
| S002 | 2017-03-16 | Normal 180 Day Track No User Fee |
| S001 | 2016-09-01 | Normal 180 Day Track No User Fee |